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INTRODUCTION
Periodontal disease (PD) shares several clinical 
and pathogenic characteristics with chronic arthritis. 
Periodontal diseases are not only a threat to dentition, 
but may also be a threat to general health. There are 
reports suggesting increased prevalence of diabetes, 
atherosclerosis, myocardial infarction, stroke, and rheu-
matoid arthritis (RA) in patients with periodontal disease 
(1,2). All forms of inflammatory periodontal diseases 
are associated with chronic inflammation (accumulation 
of B and T lymphocytes as well as of monocytes and 
neutrophils), resulting in the destruction of periodontal 
ligament and bone (3). The current paradigm for RA in-
cludes an initiating event leading to significant synovial 
inflammation and tissue destruction. As for periodontitis, 
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there is an accumulation of inflammatory cells in the 
gingiva (T and B lymphocytes, neutrophils, and mono-
cytes), tissue edema, endothelial cell proliferation, and 
matrix degradation (4).
The similarities between RA and PD have 
prompted several studies on the periodontal status of 
patients with RA although the relationship between RA 
and PD that emerged from those studies are controversial 
(5-8). in light of these reports, there is a need for further 
investigation to determine whether the severity of RA 
and PD is interrelated. A possible correlation between 
periodontal disease and rheumatoid arthritis and an 
improvement in both conditions following non-surgical 
periodontal treatment would bring benefits to the popu-
lation with both diseases. Thus, the aim of this study is 
to analyze, clinically and systemically, the association 
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between PD and RA, and if non-surgical periodontal 
treatment has any effect on the control of RA. 
MATERIAL AND METHODS
 This clinical study was carried out as a joint 
collaboration between the Division of Clinical im-
munology of the Medical school and the Department 
of Periodontology of Ribeirão Preto Dental school, 
University of são Paulo, sP, Brazil. 
The study population consisted of a sample of 
75 patients, ranging from 35-60 years of age, which 
were assigned into 5 Groups of 15 patients each, ac-
cording to the presence of the systemic diseases (RA) 
and/or periodontal diseases (PD) and to the treatment 
or not of the PD (TR). The Groups were: Group 1: 
patients with diagnosis of RA and PD who received 
non-surgical periodontal treatment (NsPT) during the 
study RA+PD+TR+ (random allocation with Group 2); 
Group 2: patients with diagnosis of RA and PD who 
were monitored during the study and did not receive 
periodontal treatment RA+PD+TR-; Group 3: patients 
with diagnosis of RA and using total prosthesis RA+TP; 
Group 4: patients with diagnosis of PD without RA 
analyzed before and after non-surgical periodontal treat-
ment RA-PD+TR+; Group 5: systemic and periodontally 
healthy patients RA-PD-.
The protocol was approved by the ethics 
Committee on human Research of the University 
hospital of Ribeirão Preto Medical school (Protocol 
#1538.0.004.000-05) and all patients gave written in-
formed consent for the treatment. The arthritis patients 
were selected according to the criteria of the American 
College of Rheumatology (9) for the diagnosis of RA 
and were treated at the University hospital.
The period from diagnosis of RA until the en-
rollment in the study varied from 6 months to 10 years. 
The medication used by the patients was maintained, 
to avoid study interferences. The patients belonged to 
the same low income class. 
The patients with periodontal disease had 2 or 
more teeth with attachment loss ≥6 mm and one or more 
teeth with probing pocket depth ≥5 mm, according to the 
criteria of Machtei et al. (10). Considering the dentate 
groups the number of teeth was about 20 in each patient.
exclusion criteria were smoking, pregnant or 
nursing women and patients with any systemic disease or 
who had used antibiotics within the previous 3 months. 
At baseline, medical and dental histories were 
recorded and various parameters were measured. Peri-
odontal clinical parameters involved were: probing 
pocket depth (PPD) measured at 6 sites/teeth using an 
electronic probe (Florida Probe Corporation, Gainesville, 
Fl, UsA), the percentage of sites presenting bleeding 
on probing (BoP) and the percentage of teeth surfaces 
which revealed the presence of dental plaque (Pl).
The activity of the RA was measured by labora-
tory tests and clinical evaluation (questionnaires of 
disease activity and physical examination).
Laboratory Methods
Rheumatoid factor (RF): igM rheumatoid fac-
tor was determined by nephelometry and used only as 
inclusion criteria. These values were extracted from the 
patients records. 
Acute-phase reaction tests: *alpha - 1 acid 
glycoprotein (AAG): the concentration of AAG was 
determined by kinetic nephelometry. The normal value 
was less than 120 mg%; *The erythrocyte sedimentation 
rate (esR): it was measured by the Wintrobe method, 
normal values are less than 10 mm/1st h for men and less 
than 20 mm/1st h for women; *C-reactive protein (CRP): 
the concentration of CRP was determined by kinetic 
nephelometry. The normal value is less than 0.5 mg/dl.
Questionnaires of Disease Activity
The Stanford Health Assessment: the hAQ has 
been established as a valuable, effective, and sensitive 
tool for measurement of health status. 
Disease Activity Score (DAS28): DAs stands 
for “Disease Activity score”, and measures the activity 
of rheumatoid arthritis. The following parameters are 
included in the calculation: number of joints that are 
tender to the touch (TeN), number of swollen joints 
(sW), erythrocyte sedimentation rate (esR) and patient 
assessment of disease activity (vAs; mm). 
Short-Form Health Survey (SF 36): sF-36 is a multi-
purpose questionnaire, with only 36 questions. it yields an 
8-scale profile (A-h) of functional health and well-being 
scores as well as a psychometrically-based physical and 
mental health summary and a preference-based health 
utility index. it is a generic measure, as opposed to one 
that targets a specific age, disease, or treatment group. An 
increased value of this data reflects patients’ improvement.
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All of these examinations and tests were made at 
baseline, 3 and 6 months after non-surgical periodontal 
treatment in Group 1 (RA+PD+TR+) and after start 
monitoring of Group 2 (RA+DP+TR-). The patients from 
Group 2, who did not receive periodontal treatment dur-
ing the study were treated after the end of the study. The 
questionnaires of disease activity showed the functional 
capacity of the patients, before and after periodontal 
treatment. in Group 4 (RA-PD+TR+) the same treatment 
was applied, without specific examinations for RA, only 
laboratory tests for acute-phase reaction (AAG, esR, 
CRP). The patients were monitored monthly. in Group 
3 (RA+TP), patients were examined just once, and all 
15 patients had their teeth extracted because of severe 
periodontal disease. Group 5 (RA-PD-) was examined 
periodontally and systemically (acute-phase reaction) 
once. These 2 Groups were used as control groups 
of the study. The non-surgical periodontal treatment 
consisted of full-mouth conventional scaling and root 
planning (sRP).
The clinical and laboratory parameters collected 
received statistical analyses at baseline, 3 and 6 months 
post-treatment. The Mann-Whitney test was performed 
to compare the differences between Groups, and the 
Friedman Anova and Wilcoxon tests were performed 
to compare the differences between the examination 
periods (baseline, 3 and 6 months) in each Group. The 
spearman correlation test was used to analyze associa-
tions between variables. All statistical analysis consid-
ered the significance level (p) of 5%. 
RESULTS
The present study did not have any sample loss; 
all the selected patients placed in their respective Groups 
finished the period of the study. in relation to the de-
mographic data, the age average of the groups was 50 
years old, and 60% of the patients were female, which 
reflected the RA incidence 3:1 (9).
Intra-Group Analysis
The PPD of group 1 (RA+PD+TR+) was statis-
tically reduced for the entire 6 months post-treatment 
period (p<0.0043), as well as the % of Pl (p<0.0016). 
There was a reduction in the % of BoP, but it was not 
statistically significant (p<0.0726). For the acute phase 
laboratory data, AAG, esR and CRP there was no sta-
tistical differences after 6 months (0-3, 0-6 and 3-6). 
The Group 2 (RA+PD+TR-) did not show sta-
tistically significant reductions for the variables PPD 
(p<0.3678), % of Pl and % of BoP. systemically, only 
esR was statistically significant for the 6 months evalu-
ation (0-6) (p=0.0007). 
For Group 4 (RA-PD+TR+) all the variables 
were significantly reduced: PPD (p<0.0001), % of Pl 
(p<0.0000) and % of BoP (p<0.0000). (Tables 1,2,3). 
systemically, AAG (p<0.0001), PCR (p<0.0000), vhs 
(p<0.0000) all had statistically significant reductions. 
These differences occurred in the examination periods 
of 0-3, 0-6, 3-6 months (Tables 6-8).
Inter-Group Analysis
The differences between Groups 1 and 4 were 
statistically significant for % of Pl (p=0.0152) for the 
evaluation between 3-6 months. Although the improve-
ments were greater for Group 1, for PPD and % of BoP, 
the differences were not statistically significant (Table 4). 
The differences for the systemic parameters AAG, esR 
and CRP were statistically significant between Groups 
1 and 4, AAG for the examination periods for 0-3 and 
0-6 months, CRP and esR in the evaluation periods of 
0-6, 3-6 months (Table 9). 
The differences between Groups 1 and 2 were sta-
tistically significant for PPD after 3 (T1-T0) (p=0.0055) 
and after 6 months (T2-T0) (p=0.0066); for the % of BoP 
it was significant after 6 months (T2-T0) (p=0.0128) 
and for the % of Pl it was significant after 3 (T1-T0) 
(p=0.0128) and 6 months (T2-T0) (p=0.0002) in favor 
of Group 1, the group that received the non-surgical 
periodontal treatment (Table 5).
Comparing the initial PPD average from Group 
4 to punctual data collected from control Group 5 
(RA-PD-) there were no statistically significant differ-
ences. (p=0.6936). The other data showed statistically 
significant differences: % of BoP (p=0.0000), % of Pl 
(p=0.0084), AAG (p=0.000), CRP (p=0.0020) and esR 
(p=0.0001). After 3 months there were no differences for 
the % of Pl (p=0.0712) and PPD (p=0.4186), although 
for the other variables there were differences: AAG 
(p=0.0000), CRP (p=0.0171), esR (p=0.0007) and % 
of BoP (p=0.000). After 6 months the PPD reduction 
for Group 4 was bigger and statistically significant 
when compared to the other groups (p=0.0005), the 
CRP (p=0.9670) and esR (p=0.0591) values were no 
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longer statistically different at this time. The differences 
in AAG (p=0.0004) continued and there were statisti-
cal differences in: % of BoP (p=0.0017) and % of Pl 
(p=0.0001) (Table 10).
Comparing Group 1 (RA+PD+TR+) to Group 5 
(RA-PD-) the variables AAG, % of BoP were statistically 
different for all 3 evaluation periods (baseline, 3 and 6 
months), being bigger for Group 5. The PPD was different 
at baseline (p=0.0001) and after 3 months (p=0.0095), % 
of Pl only at baseline (p=0.0004). CRP and esR did not 
present statistical differences in any of the evaluations 
(Table 11). Comparing Group 1 (RA+PD+TR+) to Group 
3 (RA+TP) there were statistically significant differences 
in DAs28 at baseline and after 3 months, bigger for Group 
3, but not after 6 months (Table 12).
in Group 4 correlations were found at the 0-3 
months examinations when comparing % of BoP and 
AAG (r=0.50; p<0.0281), when comparing PPD in the 
0-3 months to AAG in the 3-6 months examinations 
(r=0.80; p<0.0000) and when comparing % of Pl in 
Table 1. Mean probing pocket depth (mm) of 45 patients: 15 from Group 1 (RA+PD+TR+), 15 from Group 2 (RA+PD+TR-) and 15 
from Group 4 (RA-PD+TR+).
Patients T0initial
T1
3 months
T2
6 months Friedman
T1-T0
Wilcoxon 
T2-T1
Wilcoxon 
T2-T0
Wilcoxon 
Group 1 3.24(0.88) 2.82(0.77) 2.71(0.76) p<0.0043 p=0.0096 p=0.1579 p=0.0030
Group 2 3.12(0.47) 3.12(0.47) 3.13(0.45) p<0.3678 p=0.8886 p=0.8785 p=0.2135
Group 4 2.46(0.47) 2.11(0.51) 1.87(0.39) p<0.0001 p=0.0018 p=0.0007 p=0.0309
Mean (standard deviation). Kruskal-Wallis ANovA (testing overall difference among the three groups in the baseline - T0, p =0.0009). 
Mann-Whitney G1-G2 p=0.6041; Mann-Whitney G1-G4 p=0.0026; Mann-Whitney G2-G4 p=0.0006.
Table 2. Mean bleeding index (%) of 45 patients: 15 from Group 1 (RA+PD+TR+), 15 from Group 2 (RA+PD+TR-) and 15 from 
Group 4 (RA-PD+TR+).
Patients T0initial
T1
3 months
T2
6 months Friedman
T1-T0
Wilcoxon 
T2-T1
Wilcoxon 
T2-T0
Wilcoxon 
Group 1  49.47(35.19) 25.91(28.93) 29.78(28.93) p<0.0726 p=0.0131 p=0.7537 p=0.0110
Group 2    34.25(18.53) 34.25(18.53) 34.25(18.53) - - - -
Group 4  21.19(7.92) 12.06(6.21) 7.62(7.15) p<0.0000 p=0.0007 p=0.0007 p=0.0076
Mean (standard deviation). Kruskal-Wallis ANovA (testing overall difference among the three groups in the baseline -T0, p=0.0467). 
Mann-Whitney G1-G2 p=0.4937; Mann-Whitney G1-G4 p=0.0852; Mann-Whitney G2-G4 p=0.0114.
Table 3. Mean plaque index (%) of 45 patients: 15 from Group 1 (RA+PD+TR+), 15 from Group 2 (RA+PD+TR-) and 15 from Group 
4 (RA-PD+TR+).
Patients T0initial
T1
3 months
T2
6 months Friedman
T1-T0
Wilcoxon 
T2-T1
Wilcoxon 
T2-T0
Wilcoxon 
Group 1  83.98(25.64) 44.24(32.28) 42.90(32.17) p<0.0016 p=0.0047 p=0.6379 p=0.0022
Group 2    66.08(18.94) 66.08(18.94) 66.08(18.94) - - - -
Group 4  51.35(8.77) 35.29(16.61) 17.92(12.99) p<0.0000 p=0.0064 p=0.0007 p=0.0038
Mean (standard deviation). Kruskal-Wallis ANovA (testing overall difference among the three groups in the baseline -T0, p=0.0017). 
Mann-Whitney G1-G2 p=0.0400; Mann- Whitney G1-G4 p=0.0015; Mann-Whitney G2-G4 p=0.0294.
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the 0-3 months with reductions in the AAG in the 3-6 
months examinations (r=0.58; p<0.0114).
in the groups with RA and PD the correlations 
were not found. 
Table 5. Mean reduction of PPD (mm), % BoP, % Pl between groups.
variables Groups T1-T0mean ± sd
T2-T1
mean ± sd
T2-T0
mean ± sd
T1-T0
Mann 
Whitney
T2-T1
Mann 
Whitney
T2-T0
Mann 
Whitney
PPD
Group 1 -0.42 ± 0.50 -0.11 ± 0.27 -0.54 ± 0.49
p=0.0055 p=0.2211 p=0.0066
Group 2 -0.001 ± 0.05 -0.01 ± 0.05 -0.01 ± 0.06
%BoP
Group 1 -23.56 ± 32.53 +3.87 ± 16.31 -19.69 ± 28.53
p=0.1198 p=0.5338 p=0.0128
Group 2 - - -
%Pl
Group 1 -39.74 ± 36.54 -1.34 ± 37.97 -41.08 ± 33.79
p=0.0128 p=0.5338 p=0.0002
Group 2 - - -
PPD=probing depth; BoP=bleeding on probing; Pl=Plaque;  Group 1= RA+PD+TR+; Group 2= RA+PD+TR-.
Table 4. Mean reduction of PPD (mm), % BoP, % Pl between groups.
variables Groups T1-T0mean ± sd
T2-T1
mean ± sd
T2-T0
mean ± sd
T1-T0
Mann 
Whitney
T2-T1
Mann 
Whitney
T2-T0
Mann 
Whitney
PPD
Group 1 -0.42 ± 0.50 -0.11 ± 0.27 -0.54 ± 0.49
p=0.6334 p=0.2717 p=0.8846
Group4 -0.35 ± 0.24 -0.24 ± 0.32 -0.59 ± 0.23
%BoP
Group 1 -23.56 ± 32.53 +3.87 ± 16.31 -19.69 ± 28.53
p=0.9339 p=0.1985 p=0.8519
Group 4 -9.13 ± 4.40 -4.43 ± 4.83 -13.56 ± 4.68
%Pl
Group 1 -39.74 ± 36.54 -1.34 ± 37.97 -41.08 ± 33.79
p=0.1198 p=0.0152 p=0.7875
Group 4 -16.06 ± 15.36 -17.37 ± 18.30 -33.43 ± 11.83
PPD=probing depth; BoP=bleeding on probing; Pl=Plaque; Group 1= RA+PD+TR+; Group 4= RA-PD+TR+.
Table 6. Mean AAG (mg %) of 45 patients: 15 from Group 1 (RA+PD+TR+), 15 from Group 2 (RA+PD+TR-) and 15 from Group 
4 (RA-PD+TR+).
Patients T0initial
T1
3 months
T2
6 months Friedman
T1-T0
Wilcoxon 
T2-T1
Wilcoxon 
T2-T0
Wilcoxon 
Group 1 91.57(24.93) 92.11(27.54) 88.67(23.95) p<0.9355 - - -
Group 2 102.13(31.96) 101.67(36.33) 120.47(16.13) p<0.0707 - - -
Group 4 97.67(10.87) 86.20(10.56) 78.27(12.39) p<0.0001 p=0.0031 p=0.0012 p=0.0018
Mean (standard deviation). Kruskal-Wallis ANovA (testing overall difference among the 3 Groups in the baseline -T0, p=0.2416). 
Mann-Whitney G1-G2 p=0.1585; Mann-Whitney G1-G4 p=0.1409; Mann-Whitney G2-G4 p=0.7557.
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DISCUSSION
Chronic periodontal disease can be considered 
a potential focus of infection, which worsens the meta-
Table 7. Mean CRP (mg %) of 45 patients: 15 from Group 1 (RA+PD+TR+), 15 from Group 2 (RA+PD+TR-) and 15 from Group 4 
(RA-PD+TR+).
Patients T0initial
T1
3 months
T2
6 months Friedman
T1-T0
Wilcoxon 
T2-T1
Wilcoxon 
T2-T0
Wilcoxon 
Group 1 0.90(1.06) 0.86(1.11) 0.63(0.54) p<0.4203 - - -
Group 2 0.61(0.19) 0.55(0.18) 0.81(1.10) p<0.9252 - - -
Group 4 2.07(1.26) 1.23(0.77) 0.63(0.31) p<0.0000 p=0.0024 p=0.0022 p=0.0015
Mean (standard deviation). Kruskal-Wallis ANovA (testing overall difference among the three groups in the baseline - T0, p=0.071). 
Mann-Whitney G1-G2 p=0.2902; Mann- Whitney G1-G4 p=0.0136; Mann-Whitney G2-G4 p=0.0045.
Table 8. Mean esR (mm/h) of 45 patients: 15 from Group 1 (RA+PD+TR+), 15 from Group 2 (RA+PD+TR-) and 15 from Group 4 
(RA-PD+TR+).
Patients T0initial
T1
3 months
T2
6 months Friedman
T1-T0
Wilcoxon 
T2-T1
Wilcoxon 
T2-T0
Wilcoxon 
Group 1 24.53(13.13) 24.07(13.51) 22.40(13.13) p<0.6449 - - -
Group 2 34.80(18.08) 39.40(16.37) 28.33(8.47) p<0.0030 p=0.0535 p=0.3109 p=0.0007
Group 4 37.47(7.36) 34.67(9.59) 27.67(9.60) p<0.0000 p=0.0106 p=0.0007 p=0.0007
Mean (standard deviation). KrusKal-Wallis Anova (testing overall difference among the three groups in the baseline - T0, p=0.0158).
Mann-Whitney G1-G2 p=0.1647; Mann-Whitney G1-G4 p=0.0035; Mann-Whitney G2-G4 p=0.1776.
Table 9. Mean reduction of AAG (mg %), CRP (mg %), eRs (mm/h) between groups.
variables Groups T1-T0mean ± sd
T2-T1
mean ± sd
T2-T0
mean ± sd
T1-T0
Mann 
Whitney
T2-T1
Mann 
Whitney
T2-T0
Mann
Whitney
AAG
Group 1 +0.54 ± 27.01 -3.44 ± 18.09 -2.90 ± 20.10
p=0.0381 p=0.2902 p=0.0144
Group 4 -11.47 ± 9.65 -7.93 ± 5.80 -19.40 ± 12.56
CRP
Group 1 -0.04 ± 1.36 -0.23 ± 0.89 -0.27 ± 0.92
p=0.1095 p=0.0023 p=0.0015
Group 4 -0.84 ± 1.12 -0.59 ± 0.57 -1.43 ± 1.19
esR
Group 1 -0.47 ± 9.44 -1.67 ± 6.04 -2.13 ± 3.46
p=0.6182 p=0.0016 p=0.0019
Group 4 -2.80 ± 5.35 -7.00 ± 4.50 -9.80 ± 5.76
AAG= alpha- 1 acid glycoprotein; CRP= C-reactive protein; esR= The erythrocyte sedimentation rate. Group 1= RA+PD+TR+; 
Group 4= RA-PD+TR+.
bolic control of patients with diabetes and RA (11). The 
pathobiology of periodontal disease (PD) and rheumatoid 
arthritis (RA) is similar, both are inflammatory chronic 
diseases, with activation of complement, production of 
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Table 10. Mean reduction of AAG (mg %), CRP (mg %), eRs (mm/h), PPD (mm), % BoP, % Pl between groups.
variables Groups initialmean ± sd
3 months
mean ± sd
6 months
mean ± sd
Mann-
Whitney 
initial
Mann- 
Whitney
3 months
Mann- 
Whitney
6 months
AAG
Group 5 57.13 ± 13.39
p=0.0000 p=0.0000 p=0.0004
Group 4 97.67 ± 10.89 86.20 ± 10.56 78.27 ± 12.39
CRP
Group 5 0.61 ± 0.28
p=0.0020 p=0.0171 p=0.9670
Group 4 2.07 ± 1.26 1.23 ± 0.77 0.63 ± 0.31
esR Group 5 20.60 ± 8.70 p=0.0001 p=0.0007 p=0.0591
Group 4 37.47 ± 7.36 34.67 ± 9.59 27.67 ± 9.60
PPD
Group 5 2.29 ± 0.10
p=0.6936 p=0.4186 p=0.0005
Group 4 2.46 ± 0.47 2.10 ± 0.51 1.87 ± 0.39
%BoP Group 5 1.71 ± 0.98 p=0.0000 p=0.0000 p=0.0017
Group  4 21.18 ± 7.92 12.06 ± 6.21 7.63 ± 7.15
%Pl
Group 5 43.73 ± 6.11
p=0.0084 p=0.0712 p=0.0001
Group 4 51.35 ± 8.77 35.29 ± 16.61 17.92 ± 12.99
AAG = alpha-1 acid glycoprotein; CRP = C-reactive protein; esR = The erythrocyte sedimentation rate. PPD = probing depth; 
BoP = bleeding on probing; Pl = Plaque. Group 4 = RA-PD+TR+; Group 5 =RA-PD-.
cytokines and release of other inflammatory cell prod-
ucts (12,13). however, the relationship between the 2 
diseases is controversial, due to difficulties in analyzing 
the association between disease activities of RA and PD 
in randomized controlled studies, as described by Ribeiro 
et al. (14) and Miranda el al. (15). Therefore, further 
studies are needed to study the relationship between 
the 2 diseases (4,16). 
in the present study, the improvement in Group 1 
(RA+PD+TR+) after non-surgical periodontal treatment 
(NsPT) was statistically significant in the control of the 
periodontal disease, but the systemic values, although re-
duced, were not statistically significant. (Tables 1-3,6-8). 
When the Groups 1 (RA+PD+TR+), 2 
(RA+DP+TR-) and 4 (RA-DP+TR+) were compared at 
baseline, they were statistically different. This fact does 
not compromise the study, because in the comparison 
between groups, the reduction values were used instead 
of the means. 
Periodontal status improvement affecting the 
laboratory results (acute-phase proteins) was easier to 
be noted in Group 4, meaning that RA is a multifactorial 
disease, which makes the control of the other inflamma-
tory processes in the organism difficult (4). in Group 4 
there was a correlation between the reduction in % of 
BoP, PPD, % of Pl and reductions in AAG. 
Tables 4 and 9 compares Groups 1 and 4, show-
ing reductions in periodontal and systemic values after 
NsPT. There are increased reductions for Group 4 in 
% of Pl (T2-T1), AAG (T1-T0, T2-T0), CRP (T2-T1, 
T2-T0) and esR (T2-T1, T2-T0). This result could be 
due to the initial differences between Groups, observing 
the initial mean values and their standard deviations. 
The % of Pl was lower in Group 4, in part, because 
of the patients’ compliance, since patients of Group 1 
were less motivated, considering emotional factors and 
physical limitations caused by the  symptoms of RA. 
Comparing Groups with RA, 1 and 2, large 
reductions were noted in the Groups treated in all the 
parameters (periodontal, systemic and specific RA 
tests). This result suggests the necessity of patients with 
RA to receive periodontal treatment, even though the 
correlation was not totally clear. it could be explained 
by the difficulties to work with multifactorial systemic 
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Table 11. Mean reduction of AAG (mg %), CRP (mg %), eRs (mm/h), PPD (mm), % BoP, % Pl between groups.
variables Groups initialmean ± sd
3 months
mean ± sd
6 months
mean ± sd
Mann-
Whitney 
initial
Mann- 
Whitney
3 months
Mann- 
Whitney
6 months
AAG
Group 5 57.13 ± 13.39
p=0.0002 p=0.0001 p=0.0001
Group 1 91.57 ± 24.93 92.11 ± 27.54 88.67 ± 23.95
CRP
Group 5 0.61 ± 0.28
p=0.5897 p=0.3297 p=0.6041
Group 1 0.90 ± 1.06 0.86 ± 1.11 0.63 ± 0.54
esR Group 5 20.60 ± 8.70 p=0.2998 p=0.6187 p=0.8682
Group 1 24.53 ± 13.13 24.07 ± 13.51 22.40 ± 13.13
PPD
Group 5 2.29 ± 0.10
p=0.0001 p=0.0095 p=0.0779
Group 1 3.24 ± 0.88 2.82 ± 0.77 2.71 ± 0.76
%BoP Group 5 1.71 ± 0.98 p=0.0000 p=0.0000 p=0.0000
Group 1 49.47 ± 35.19 25.91 ± 28.93 29.78 ± 28.93
%Pl
Group 5 43.73 ± 6.11
p=0.0004 p=0.0852 p=0.1409
Group 1 83.98 ± 25.64 44.24 ± 32.28 42.90 ± 32.17
AAG= alpha- 1 acid glycoprotein; CRP= C-reactive protein; esR= The erythrocyte sedimentation rate.
PPD=probing depth; BoP=bleeding on probing; Pl=Plaque.
Group 1= RA+PD+TR+; Group5=RA-PD-.
diseases and the difficulties of getting a larger numbers 
of patients for each Group (n=15). 
Comparing Groups 4 (RA-DP+TR+) and 5 
(RA-PD-), PPD was not statistically significant only at 
baseline. After 3 months PPD and % of Pl and after 6 
months CRP and esR were not statistically different. 
This shows the reduction of acute-phase proteins by the 
periodontal treatment and that after 6 months the test 
Group became similar to the control Group, demonstrat-
ing a healthy profile. 
This same observation was difficult to be detected 
when comparing Groups 1 (RA+PD+TR+) and 5 (RA-
PD-) because the values were statistically significant: 
AAG and % of BoP were maintained during the evalu-
ation periods, despite the reductions in the test group. % 
of Pl was not statistically different after 3 months and 
PPD after 6 months. The improvement of PPD and % of 
Pl was evident, but not for the systemic parameters. This 
could be explained by the continuous use of systemic 
medications (sAiDs and NsAiDs drugs) by RA patients 
that results in control of the acute phase proteins and 
RA, and since RA is a multifactorial systemic disease, 
the clinical improvements, after periodontal treatment, 
are more difficult to be detected.
Considering Group 1, the periodontal improve-
ment did not correlate to the laboratory values. This could 
be due to the small size of the sample, with non-normal 
distributions, being evident the necessity of a descriptive 
analysis of the data. 
so, even if the correlations were not so clear, con-
sidering the reduction values and the dispersion points 
in the correlation graphs, it was possible to see that the 
laboratory results and specific tests for RA improved or 
were controlled by the periodontal treatment. 
Analyzing the periodontal status, the patients 
from Group 1 (RA+PD+TR+) were similar to healthy 
patients, although their acute phase proteins presented 
higher values. The chronic used drugs (sAiDs and 
NsAiDs) by the RA patients to mitigate symptoms of 
the disease could affect the progression of bone loss, but 
not the clinical periodontal improvement (16-18). Thus, 
the difficulty to show a correlation between RA and PD 
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Table 12. Mean reduction of AAG (mg %), CRP (mg %), eRs (mm/h), PPD (mm), % BoP, % Pl between groups.
variables Groups initialmean ± sd
3 months
mean ± sd
6 months
mean ± sd
Mann-
Whitney 
initial
Mann- 
Whitney
3 months
Mann- 
Whitney
6 months
AAG
Group 1 91.57 ± 24.93 92.11 ± 27.54 88.67 ± 23.95
p=0.9010 p=0.9504 p=0.6187
Group 3 90.72 ± 21.96
CRP
Group 1 0.90 ± 1.06 0.86 ± 1.11 0.63 ± 0.54
p=0.9174 p=0.9339 p=0.9010
Group 3 0.79 ± 0.83
esR Group 1 24.53 ± 13.13 24.07 ± 13.51 22.40 ± 13.13 p=07875 p=04679 p=0.3837
Group 3 27.20 ± 15.20
hAQ Group 1 1.22 ± 0.81 1.16 ± 0.71 0.91 ± 0.54 p=0.2290 p=0.1844 p=0.4807
Group 3 0.83 ± 0.64
DAs28
Group 1 3.34 ± 1.14 2.69 ± 0.88 2.25 ± 0.66
p=0.0062 p=0.0381 p=0.5755
Group 3 2.14 ± 0.76
sFA
Group 1 52.67 ± 31.05 62.33 ± 24.70 64.33 ± 25.13
p=0.2540 p=0.6482 p=1
Group 3 66.00 ± 15.61
sFB
Group 1 54.67 ± 41.25 68.67 ± 28.88 72.33 ± 25.97
p=0.8035 p=0.4807 p=0.1985
Group 3 61.33 ± 15.75
sFC
Group 1 50.13 ± 30.52 64.40 ± 25.69 66.23 ± 24.56
p=0.1914 =0.8682 p=0.8357
Group 3 64.80 ± 18.85
AAG= alpha- 1 acid glycoprotein; CRP= C-reactive protein; esR= The erythrocyte sedimentation rate.
hAQ= The stanford health Assessment; DAs28= Disease Activity score; sF36= short-Form health survey.
Group 1= RA+PD+TR+; Group 3=RA+TP.
could be associated with the chronic use of drugs. The 
fact that many of the clinical studies available compar-
ing the periodontal status to RA are transversal studies 
increases the difficulties in evaluating important points 
such as tooth loss (8,19).
in Groups 1 (RA+PD+TR+) and 3 (RA+TP) 
there was a statistical difference at baseline and the 
3 months evaluation for the DAs28, but not for the 6 
months evaluation, favoring Group 1. This shows that 
RA patients do not need to have their teeth extracted 
in order to control the disease, point which was raised 
also by PAGe (20).
The control of the inflammatory activity improved 
the periodontal status in systemically healthy patients. 
Although there was an improvement in the periodontal 
status of RA patients, the inflammatory activity was not 
significantly reduced. This can be explained by the fact 
that RA patients have other sites that contribute to the 
inflammatory panorama besides the oral cavity. 
in conclusion, although the relation between 
RA and PD, is not clear, it is possible to indicate the 
importance of the periodontal treatment in the control 
of inflammation, in order to avoid tooth extractions and 
to guarantee benefits for the patients with RA. 
RESUMO
este estudo avaliou a influência da doença periodontal (DP) na 
artrite reumatóide (AR). 75 pacientes, 35-60 anos, divididos em 
5 Grupos, considerando a situação sistêmica e periodontal foram 
analisados. Um Grupo usava prótese total (PT). os parâmetros 
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clínicos e laboratoriais analisados: inicial, 3 e 6 meses receberam 
tratamento estatístico. As correlações entre as reduções da profun-
didade de sondagem, placa microbiana e sangramento à sondagem 
com as de Alfa 1, PCR, vhs e exames de qualidade de vida 
(hAQ, DAs28, sF36) foram também analisadas. Comparando o 
Grupo 1 (AR+DP+TR+) e Grupo 2 (AR+DP+TR-), aqueles que 
receberam tratamento periodontal não-cirúrgico (TPNC) tiveram 
reduções estatisticamente significativas em relação a Ps aos 3 
meses (p=0,0055) e 6 meses (p=0,0066); as reduções da % ss 
foram estatisticamente significantes aos 6 meses (p=0,0128) e 
da % PM aos 3 (p=0,0128) e 6 meses (p=0,0002). o TPNC não 
apresentou correlação com a melhora dos exames laboratoriais, 
nem com os exames de qualidade de vida. Comparando o Grupo 
1 com o Grupo 3 (AR+PT) houve diferença estatisticamente sig-
nificante no DAs28 inicial e 3 meses. Não foi possível verificar 
uma correlação direta do TPNC na atividade da doença sistêmica, 
mas pode-se constatar a sua importância, evitando a extração 
múltipla dos dentes. 
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